Neuropilin 1 Promotes Epithelial to Mesenchymal Transition by Stimulating Nuclear Factor Kappa B and Is Associated with Poor Prognosis in Human Oral Squamous Cell Carcinoma
Background The epithelial to mesenchymal transition (EMT) is a key process in carcinogenesis, invasion, and metastasis of oral squamous cell carcinoma (OSCC) In our previous studies, we found that neuropilin 1 (NRP1) is overexpressed in tongue squamous cell carcinoma and that this overexpression is associated with cell migration and invasion. Nuclear factor kappa B (NF kB) plays an essential role both in the induction and the maintenance of EMT and tumor metastasis. Therefore, we hypothesized that NRP1 induces EMT, and that NRP1 induced migration and invasion may be an important mechanism for promoting invasion and metastasis of OSCC through NF kB activation. Methods/Results The variations in gene and protein expression and the changes in the biological behavior of OSCC cell lines transfected with a vector encoding NRP1, or the corresponding vector control, were evaluated. NRP1 overexpression promoted EMT and was associated with enhanced invasive and metastatic properties. Furthermore, the induction of EMT promoted the acquisition of some cancer stem cell (CSC) like characteristics in OSCC cells. We addressed whether selective inhibition of NF kB suppresses the NRP1 mediated EMT by treating cells with pyrrolidinedithiocarbamate ammonium (PDTC) an inhibitor of NF kB. Immunohistochemical analysis of NRP1 in OSCC tissue samples further supported a key mediator role for NRP1 in tumor progression, lymph node metastasis, and indicated that NRP1 is a predictor for poor prognosis in OSCC patients. Conclusion Our results indicate that NRP1 may regulate the EMT process in OSCC cell lines through NF kB activation, and that higher NRP1 expression levels are associated with lymph node metastasis and poor prognosis in OSCC patients. Further investigation of the role of NRP1 in tumorigenesis may help identify novel targets for the prevention and therapy of oral cancers.
PloS one